UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


March 13, 2019

Date of Report


Cantabio Pharmaceuticals Inc.

(Exact name of small business issuer as specified in its charter)


Delaware

 

000-54905

 

99-0373067

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification

No.)


2225 East Bayshore Road, Suite 200

Palo Alto, CA 94303

 

94303

(Address of principal executive offices)

 

(Zip Code)


(844) 200-2826

Registrant’s telephone number, including area code


1250 Oakmead Pkwy

Sunnyvale, CA 94085

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


[  ]

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[  ]

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[  ]

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[  ]

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [   ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [    ]





Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On March 13, 2019, Simon Peace’s employment agreement as the Chief Financial Officer of Cantabio Pharmaceuticals Inc. (the “Company”) expired, and Mr. Peace is no longer our Chief Financial Officer. The vacancy of Chief Financial Officer will not be filled until such time as the Board of Directors has identified a qualified candidate to fill such vacancy.



































2




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

CANTABIO PHARMACEUTICALS INC.

 

 

Date: March 21, 2019

By:

Name:

Title:

/s/ Thomas Roger Sawyer

Thomas Roger Sawyer

Chief Operating Officer






























3